Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs Investigator Selected Regimens in Advanced TNBC
NCT05347134Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Kelun-Biotech. Started Jun 2022; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05347134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347134.